Fig. 7: SUMOylation inhibition restores the anti-fibrotic activity of OCA in NASH models.
From: SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Mice were fed with HFHC a–d or MCD e–h diet to induce NASH-associated fibrosis and treated with OCA in the presence or absence of SP. n = 6 biologically independent samples within these experiments. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson, and Sirius red staining of liver sections (representative of n = 6 biologically independent samples. Scale bar, 100 μm). d and h mRNA expression of pro-fibrotic genes. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
